Halicin Reduces the Warburg Effect and Overcomes Drug Resistance by Activating the Pyruvate Kinase M2 Pathway for Triple-Negative Breast Cancer Treatment.

Han Gu, Wei You, Xiao-Hong Zhou, Zhe Wang, Shao-Hu Huo, Xuan Nie, Yu-Bin Feng, Ye-Zi You, Xiang Zhan, Lei Xia

Abstract read

In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Han GuDepartment of Polymer Science and Engineering, University of Science and Technology of China, Hefei, Anhui 230026, P. R. China.

Wei YouDepartment of Polymer Science and Engineering, University of Science and Technology of China, Hefei, Anhui 230026, P. R. China.

Xiao-Hong ZhouDepartment of Polymer Science and Engineering, University of Science and Technology of China, Hefei, Anhui 230026, P. R. China.ORCID https://orcid.org/0009-0008-5495-3698

Zhe WangDepartment of Polymer Science and Engineering, University of Science and Technology of China, Hefei, Anhui 230026, P. R. China.

Shao-Hu HuoDepartment of Pediatrics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P. R. China.

Xuan NieThe Department of Pharmacy, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China. Anhui Provincial Key Laboratory of Precision Pharmaceutical Preparation and Clinical Pharmacy, Hefei, Anhui 230026, P. R. China.

Yu-Bin FengThe Department of Pharmacy, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China. Anhui Provincial Key Laboratory of Precision Pharmaceutical Preparation and Clinical Pharmacy, Hefei, Anhui 230026, P. R. China.

Ye-Zi YouDepartment of Polymer Science and Engineering, University of Science and Technology of China, Hefei, Anhui 230026, P. R. China.ORCID https://orcid.org/0000-0003-0319-4165

Xiang ZhanDepartment of Gastroenterology, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, P. R. China.

Lei XiaDepartment of Polymer Science and Engineering, University of Science and Technology of China, Hefei, Anhui 230026, P. R. China.ORCID https://orcid.org/0009-0007-9822-0624

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer represents the most common cancer among women worldwide. Triple-negative breast cancer (TNBC), a particularly aggressive, metastatic, and drug-resistant subtype of breast cancer, poses a significant clinical challenge because of its resistance to treatment. The efficacy of commonly employed chemotherapeutic agents, such as paclitaxel, is severely limited. In this study, we identified the chemical compound Halicin, which inhibits the proliferation of various cancers, including TNBC.

Identifiers

PMID40547617

DOI10.1021/acsomega.5c01251

PMCPMC12177588

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.